Works by Roberts-Rapp, Lisa

Results: 10
    1
    2

    Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

    Published in:
    Neuro-Oncology, 2019, v. 21, n. 1, p. 106, doi. 10.1093/neuonc/noy091
    By:
    • Lassman, Andrew B;
    • Bent, Martin J van den;
    • Gan, Hui K;
    • Reardon, David A;
    • Kumthekar, Priya;
    • Butowski, Nicholas;
    • Lwin, Zarnie;
    • Mikkelsen, Tom;
    • Nabors, Louis B;
    • Papadopoulos, Kyriakos P;
    • Penas-Prado, Marta;
    • Simes, John;
    • Wheeler, Helen;
    • Walbert, Tobias;
    • Scott, Andrew M;
    • Gomez, Erica;
    • Lee, Ho-Jin;
    • Roberts-Rapp, Lisa;
    • Xiong, Hao;
    • Ansell, Peter J
    Publication type:
    Article
    3

    Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.

    Published in:
    Neuro-Oncology, 2018, v. 20, n. 6, p. 838, doi. 10.1093/neuonc/nox202
    By:
    • Gan, Hui K.;
    • Reardon, David A.;
    • Lassman, Andrew B.;
    • Merrell, Ryan;
    • van den Bent, Martin;
    • Butowski, Nicholas;
    • Lwin, Zarnie;
    • Wheeler, Helen;
    • Fichtel, Lisa;
    • Scott, Andrew M.;
    • Gomez, Erica J.;
    • Fischer, JuDee;
    • Mandich, Helen;
    • Hao Xiong;
    • Ho-Jin Lee;
    • Munasinghe, Wijith P.;
    • Roberts-Rapp, Lisa A.;
    • Ansell, Peter J.;
    • Holen, Kyle D.;
    • Kumthekar, Priya
    Publication type:
    Article
    4

    Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

    Published in:
    Neuro-Oncology, 2017, v. 19, n. 7, p. 965, doi. 10.1093/neuonc/now257
    By:
    • Reardon, David A.;
    • Lassman, Andrew B.;
    • van den Bent, Martin;
    • Kumthekar, Priya;
    • Merrell, Ryan;
    • Scott, Andrew M.;
    • Fichtel, Lisa;
    • Sulman, Erik P.;
    • Gomez, Erica;
    • Fischer, JuDee;
    • Ho-Jin Lee;
    • Munasinghe, Wijith;
    • Hao Xiong;
    • Mandich, Helen;
    • Roberts-Rapp, Lisa;
    • Ansell, Peter;
    • Holen, Kyle D.;
    • Gan, Hui K.
    Publication type:
    Article
    5

    Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

    Published in:
    2018
    By:
    • Goss, Glenwood D.;
    • Vokes, Everett E.;
    • Gordon, Michael S.;
    • Gandhi, Leena;
    • Papadopoulos, Kyriakos P.;
    • Rasco, Drew W.;
    • Fischer, JuDee S.;
    • Chu, Katharine L.;
    • Ames, William W.;
    • Mittapalli, Rajendar K.;
    • Lee, Ho‐Jin;
    • Zeng, Jiewei;
    • Roberts‐Rapp, Lisa A.;
    • Loberg, Lise I.;
    • Ansell, Peter J.;
    • Reilly, Edward B.;
    • Ocampo, Christopher J.;
    • Holen, Kyle D.;
    • Tolcher, Anthony W.;
    • Lee, Ho-Jin
    Publication type:
    journal article
    6

    Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

    Published in:
    2017
    By:
    • Bent, Martin;
    • Gan, Hui;
    • Lassman, Andrew;
    • Kumthekar, Priya;
    • Merrell, Ryan;
    • Butowski, Nicholas;
    • Lwin, Zarnie;
    • Mikkelsen, Tom;
    • Nabors, Louis;
    • Papadopoulos, Kyriakos;
    • Penas-Prado, Marta;
    • Simes, John;
    • Wheeler, Helen;
    • Walbert, Tobias;
    • Scott, Andrew;
    • Gomez, Erica;
    • Lee, Ho-Jin;
    • Roberts-Rapp, Lisa;
    • Xiong, Hao;
    • Bain, Earle
    Publication type:
    journal article
    7
    8

    Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.

    Published in:
    Journal of Neuro-Oncology, 2019, v. 144, n. 1, p. 205, doi. 10.1007/s11060-019-03222-y
    By:
    • Lassman, Andrew B.;
    • Aldape, Kenneth D.;
    • Ansell, Peter J.;
    • Bain, Earle;
    • Curran, Walter J.;
    • Eoli, Marica;
    • French, Pim J.;
    • Kinoshita, Manabu;
    • Looman, Jim;
    • Mehta, Minesh;
    • Muragaki, Yoshihiro;
    • Narita, Yoshitaka;
    • Ocampo, Christopher;
    • Roberts-Rapp, Lisa;
    • Song, Minghao;
    • Vogelbaum, Michael A.;
    • Walenkamp, Annemiek M. E.;
    • Wang, Tony J. C.;
    • Zhang, Peixin;
    • van den Bent, Martin J.
    Publication type:
    Article
    9

    A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3
    By:
    • Cleary, James M.;
    • Calvo, Emiliano;
    • Moreno, Victor;
    • Juric, Dejan;
    • Shapiro, Geoffrey I.;
    • Vanderwal, Carol Ann;
    • Hu, Beibei;
    • Gifford, Maryella;
    • Barch, David;
    • Roberts-Rapp, Lisa;
    • Ansell, Peter J.;
    • Xiong, Hao;
    • Ocampo, Christopher;
    • Tolcher, Anthony W.
    Publication type:
    Article
    10